A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)

Inclusion Criteria:

* Pathologically/histologically confirmed solid tumor (metastatic or locally advanced disease) that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist.
* Participants of childbearing potential must have negative pregnancy test; females and males must agree to use effective contraception during the course of the trial and for 90 days after stopping study drug.
* For Part 1b and Part 2, participant with metastatic melanoma or metastatic colorectal cancer with at least one measurable lesion
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with a life expectancy of ≥3 months.
* Adequate organ function.

Exclusion Criteria:

* Unstable or progressing central nervous system (CNS) metastasis unless asymptomatic for 3 months, with no need for steroids or antiseizure medications.
* Active gastrointestinal disease or a disorder or a history of surgery that significantly alters gastrointestinal motility or absorption.
* Has not recovered from previous therapy and had any chemotherapy, biologic, or hormonal therapy within 4 weeks of study enrollment.
* Radiation therapy (except palliative radiation to bone lesions) within 4 weeks of study enrollment.
* More than 3 prior regimens of chemotherapy, biologic therapy, hormonal therapy, or investigational drugs not including adjuvant or neoadjuvant treatments.
* Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic diseases.
* Mean QTcF interval (interval on the electrocardiogram corrected for heart rate using Fridericia's correction) \> 450 msec at baseline.
* Known Human Immunodeficiency Virus (HIV) infection, hepatitis infection, or tuberculosis infection.
* Current participation in any other interventional clinical study.
* History of significant eye disease, including glaucoma, retinopathy, or retinal vein occlusion.